Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Folic acid treatment protective against CKD progression in certain patients

16 Nov 2019

Fortification or supplementation with folic acid may confer benefits for reducing the likelihood of chronic kidney disease (CKD) progression among patients with mild-to-moderate disease and elevated vitamin B12 levels, a recent study has found.

Researchers performed a posthoc analysis using data from the kidney disease substudy of the China Stroke Primary Prevention Trial (CSPPT), including 1,374 hypertensive adults with mild-to-moderate CKD. All participants had low folate intake and had undergone vitamin B12 measurements at baseline.

The participants were assigned to a double-blinded daily treatment of enalapril 10 mg alone or in combination with folic acid 0.8 mg. The primary endpoint was progression of CKD, defined as a reduction in estimated glomerular filtration rate (eGFR) ≥30 percent and to a level of <60 mL/min/1.73 m2 if baseline eGFR was ≥60 mL/min/1.73 m2; or a decrease in eGFR ≥50 percent if baseline value was <60 mL/min/1.73 m2; or kidney failure.

Mean eGFR at baseline in the cohort was 86.1 mL/min/1.73 m2, and the median treatment duration was 4.4 years. Compared with enalapril monotherapy, treatment with the enalapril–folic acid combo yielded an 83-percent reduction in the odds of CKD progression among participants with higher baseline B12 levels (≥248 pmol/L; odds ratio [OR], 0.17, 95 percent confidence interval [CI], 0.07–0.40).

The beneficial effect on the risk of progression was not observed among participants with lower baseline B12 levels (<248 pmol/L; metabolic B12 deficiency; OR, 1.21, 95 percent CI, 0.51–2.85). Baseline vitamin B12 levels had a significant interaction with folic acid treatment (p=0.001).

There were several limitations to the study, including those inherent in a posthoc analysis and the low event rate.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.